Event Type: Q1 FY'27 Earnings Conference Call hosted by Systematix Institutional Equities

Date and Time: Monday, 20th July 2026 (specific time not mentioned in transcript)

Purpose: Discussion of quarterly results for Q1 FY27 ended 30th June 2026, business updates, and growth outlook across service segments

Management Participants:

  • Ms. Harita Vasireddi – Managing Director
  • Mr. Satya Sreenivas Neerukonda – Executive Director
  • Mr. Siva Rama Krishna – Chief Financial Officer
  • Ms. Sujani Vasireddi – Company Secretary

Availability of Materials: The investor presentation and financial results were available on the company's website and stock exchanges. The conference call was recorded, and the transcript along with the audio was made available on the company's website (https://vimta.com/investor-earnings-call/) and stock exchanges.

Compliance Statement: The management noted that anything said on the call reflecting outlook for the future or construed as forward-looking statements must be reviewed in conjunction with the risks that the company faces. The audio of the conference call is copyright material of Vimta Labs Limited and cannot be copied, rebroadcasted, or attributed in press or media without specific written consent.

Financial Period Discussed: Q1 FY27 (quarter ended 30th June 2026)

Financial Highlights Disclosed:

  • Total income: INR1,129 million (up 13.7% YoY from INR993 million in Q1 FY26)
  • EBITDA: INR411 million (up 16% YoY from INR354 million in Q1 FY26)
  • EBITDA margin: 36.4%
  • PAT: INR210 million (up 11.4% YoY from INR189 million in Q1 FY26)
  • PAT margin: 18.6%
  • Cash and cash equivalents: INR628.2 million
  • Net debt-free balance sheet

Business Segment Updates:

  • Pharma contract research and testing services: Consistent performance, broadly stable QoQ, strong YoY growth
  • Clinical research operations: Showing encouraging signs of recovery with healthy enquiries and order inflows
  • Environment division: Integrated with food division due to relative scale
  • Food testing business: Decline in import and export related sample receipts due to global challenges; focusing on domestic market
  • Electronics and electrical testing business: Remained stable during quarter; manpower challenges addressed
  • Biologics initiative: Secured first order and operationalized facility

Forward-looking Statements:

  • Capex budget: Approximately INR80 crores for FY27 to strengthen analytical capabilities and expand select service offerings
  • INR10 crores remaining for biologics CRADS facility out of total INR35 crores budget
  • Expect margins to not go down further as business grows in coming quarters
  • Positive enquiry trends and healthy demand visibility across markets
  • Biologics segment expected to contribute significantly from third year onwards

Additional Notes Section

The document contains the full transcript of the Q1 FY27 earnings conference call held on 20th July 2026. The transcript includes detailed management commentary on financial performance, business segment updates, and comprehensive Q&A session with analysts and investors.

Financial data was disclosed in the transcript including revenue figures, profitability metrics, capex plans, and segment-wise performance commentary.

The call featured participation from multiple institutional and individual investors representing firms including Trinetra Asset Managers, Molecule Ventures, Sapphire Capital, ChrysCapital, First Assets, Niveshaay Investment Advisors, Silvercoin, Sushil Financial Services, Vaikairya, and others.